Chandler N Hudson1, Kai He1, Laura E Pascal1,2,3, Teresa Liu4, Livianna K Myklebust4, Rajiv Dhir5, Pooja Srivastava5, Naoki Yoshimura1,3, Zhou Wang1,2,3, William A Ricke4, Donald B DeFranco1,6. 1. Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine Pittsburgh, PA, USA. 2. Department of Urology, University of Pittsburgh School of Medicine Pittsburgh, PA, USA. 3. UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine Pittsburgh, PA, USA. 4. Department of Urology, University of Wisconsin Madison, WI, USA. 5. Department of Pathology, UPMC, University of Pittsburgh School of Medicine Pittsburgh, PA, USA. 6. Pittsburgh Institute for Neurodegenerative Diseases, University of Pittsburgh School of Medicine Pittsburgh, PA, USA.
Abstract
BACKGROUND: Prostatic inflammation is closely linked to the development and progression of benign prostatic hyperplasia (BPH). Clinical studies of non-steroidal anti-inflammatory drugs, which inhibit cyclooxygenase-2 (COX-2), targeting prostate inflammation patients with symptomatic BPH have demonstrated conflicting results, with some studies demonstrating symptom improvement and others showing no impact. Thus, understanding the role of the cyclooxygenases in BPH and prostatic inflammation is important. METHODS: The expression of COX-1 was analyzed in a cohort of donors and BPH patients by immunohistochemistry and compared to previously determined characteristics for this same cohort. The impact of mitochondrial dysfunction on COX-1 and COX-2 was determined in experiments treating human benign prostate epithelial cell lines BPH-1 and RWPE-1 with rotenone and MitoQ. RWPE-1 cells were transfected with small interfering RNA specific to complex 1 gene NDUFS3. RESULTS: COX-1 expression was increased in the epithelial cells of BPH specimens compared to young healthy organ donor and normal prostate adjacent to BPH and frequently co-occurred with COX-2 alteration in BPH patients. COX-1 immunostaining was associated with the presence of CD8+ cytotoxic T-cells, but was not associated with age, prostate size, COX-2 or the presence of CD4+, CD20+ or CD68+ inflammatory cells. In cell line studies, COX protein levels were elevated following treatment with inhibitors of mitochondrial function. MitoQ significantly decreased mitochondrial membrane potential in RWPE-1 cells. Knockdown of NDUFS3 stimulated COX-1 expression. CONCLUSION: Our findings suggest COX-1 is elevated in BPH epithelial cells and is associated with increased presence of CD8+ cytotoxic T-cells. COX-1 can be induced in benign prostate epithelial cells in response to mitochondrial complex I inhibition, and knockdown of the complex 1 protein NDUFS3. COX-1 and mitochondrial dysfunction may play more of a role than previously recognized in the development of age-related benign prostatic disease. AJCEU
BACKGROUND: Prostatic inflammation is closely linked to the development and progression of benign prostatic hyperplasia (BPH). Clinical studies of non-steroidal anti-inflammatory drugs, which inhibit cyclooxygenase-2 (COX-2), targeting prostate inflammation patients with symptomatic BPH have demonstrated conflicting results, with some studies demonstrating symptom improvement and others showing no impact. Thus, understanding the role of the cyclooxygenases in BPH and prostatic inflammation is important. METHODS: The expression of COX-1 was analyzed in a cohort of donors and BPH patients by immunohistochemistry and compared to previously determined characteristics for this same cohort. The impact of mitochondrial dysfunction on COX-1 and COX-2 was determined in experiments treating human benign prostate epithelial cell lines BPH-1 and RWPE-1 with rotenone and MitoQ. RWPE-1 cells were transfected with small interfering RNA specific to complex 1 gene NDUFS3. RESULTS: COX-1 expression was increased in the epithelial cells of BPH specimens compared to young healthy organ donor and normal prostate adjacent to BPH and frequently co-occurred with COX-2 alteration in BPH patients. COX-1 immunostaining was associated with the presence of CD8+ cytotoxic T-cells, but was not associated with age, prostate size, COX-2 or the presence of CD4+, CD20+ or CD68+ inflammatory cells. In cell line studies, COX protein levels were elevated following treatment with inhibitors of mitochondrial function. MitoQ significantly decreased mitochondrial membrane potential in RWPE-1 cells. Knockdown of NDUFS3 stimulated COX-1 expression. CONCLUSION: Our findings suggest COX-1 is elevated in BPH epithelial cells and is associated with increased presence of CD8+ cytotoxic T-cells. COX-1 can be induced in benign prostate epithelial cells in response to mitochondrial complex I inhibition, and knockdown of the complex 1 protein NDUFS3. COX-1 and mitochondrial dysfunction may play more of a role than previously recognized in the development of age-related benign prostatic disease. AJCEU
Authors: Xinzhi Li; Liudmila L Mazaleuskaya; Chong Yuan; Laurel L Ballantyne; Hu Meng; William L Smith; Garret A FitzGerald; Colin D Funk Journal: J Lipid Res Date: 2017-11-27 Impact factor: 5.922
Authors: Laura E Pascal; Rajiv Dhir; Goundappa K Balasubramani; Wei Chen; Chandler N Hudson; Pooja Srivastava; Anthony Green; Donald B DeFranco; Naoki Yoshimura; Zhou Wang Journal: Am J Clin Exp Urol Date: 2021-02-15
Authors: Siobhan Sutcliffe; Robert L Grubb Iii; Elizabeth A Platz; Lawrence R Ragard; Thomas L Riley; Sally S Kazin; Richard B Hayes; Ann W Hsing; Gerald L Andriole Journal: BJU Int Date: 2012-03-19 Impact factor: 5.588
Authors: Marta N Valcárcel-Ares; Romina R Riveiro-Naveira; Carlos Vaamonde-García; Jesús Loureiro; Laura Hermida-Carballo; Francisco J Blanco; María J López-Armada Journal: Rheumatology (Oxford) Date: 2014-03-07 Impact factor: 7.580